ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 40 citations in OpenAlex.
- Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.Journal for immunotherapy of cancer · 2021Trial
- Anthralin-From Psoriasis Drug to Power Adjuvant.Vaccines · 2026Review
- Mediators of Inflammation in Topical Therapy of Skin Cancers.Mediators of inflammation · 2019Review
- Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
- Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.Cancer immunology, immunotherapy : CII · 2012Article
- Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis.Frontiers in neurology · 2012Article
- Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.PloS one · 2011Article
- Article
- Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.Infection and immunity · 2009Article
- Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.Clinical reviews in allergy & immunology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Much attention has been focused on transcutaneous immunization strategies to stimulate systemic cytotoxic T lymphocyte responses leading to anti-tumor or anti-microbial immunity. Here we report that topical application of vaccines consisting of synthetic peptides formulated with imiquimod, a Toll-like receptor agonist that functions as a potent adjuvant generates strong T cell responses that exhibit effective anti-tumor effects in a murine melanoma model system. These results support the use of peptide-based transcutaneous vaccines as a noninvasive and effective strategy for anti-tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.